The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
Open accessAbstract
Purpose: The anti–programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)–positive advanced solid tumors. Results from the esophageal carcinoma cohort are reported herein. Patients and Methods: Eligible patients with squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction in whom standard therapy failed and who had PD-L1–positive tumors received pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until confirmed disease progression or intolerable toxicity. Response was assessed every 8 weeks up to 6 months and every 12 weeks thereafter. Primary end points were safety and overall response rate, determined by investigator review per Response Evaluation Criteria in Solid Tumors (version 1.1). Results: Among 83 patients with esophageal carcinoma and samples evaluable for PD-L1 expression, 37 (45%) had PD-L1–positive tumors, and 23 were enrolled. Median age was 65 years; 78% had squamous histology; and 87% received ≥ two prior therapies for advanced/metastatic disease. As of the data cutoff (February 20, 2017), median follow-up was 7 months (range, 1 to 33 months). Nine patients (39%) experienced treatment-related adverse events, most commonly decreased appetite, decreased lymphocyte count, generalized rash, and rash (two patients [9%] each). No grade 4 adverse events or deaths were attributed to pembrolizumab. Overall response rate was 30% (95% CI, 13% to 53%); median duration of response was 15 months (range, 6 to 26 months). A six-gene interferon-γ gene expression signature analysis suggested that delayed progression and increased response occur among pembrolizumab-treated patients with higher interferon-γ composite scores. Conclusion: Pembrolizumab demonstrated manageable toxicity and durable antitumor activity in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Integrated genomic characterization of oesophageal carcinoma
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,821
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“On the basis of a six-gene interferon-g gene expression signature analysis of CXCL9, CXCL10, HLA-DRA, IDO1, IFNG, and STAT1, delays in progression and increased clinical response tended to occur among pembrolizumab-treated patients with esophageal carcinoma and higher signature scores, consistent with findings publish…”
ResultSelf-citationMuro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Self-citationOhigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
Carter, L. L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., & Carreno, B. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9 · Cited by 673
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Schumacher, K., Haensch, W., Röefzaad, C., & Schlag, P. M. (2001) · PubMed · Cited by 503
PD‐1 as a potential target in cancer therapy
McDermott, D. F., & Atkins, M. B. (2013) · Cancer Medicine · doi:10.1002/cam4.106 · Cited by 414
He, J., Hu, Y., Hu, M., & Li, B. (2015) · Scientific Reports · doi:10.1038/srep13110 · Cited by 401
Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30181-x · Cited by 377
Cho, Y., Miyamoto, M., Kato, K., Fukunaga, A., Shichinohe, T., Kawarada, Y., Hida, Y., Oshikiri, T., Kurokawa, T., Suzuoki, M., et al. (2003) · PubMed · Cited by 278
Targeted Therapies for Esophageal Cancer
Tew, W. P., Kelsen, D. P., & Ilson, D. H. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-590 · Cited by 154
Lv, L. L., Pan, K., Li, X.-D., She, K.-L., Zhao, J.-J., Wang, W., Chen, J.-G., Chen, Y.-B., Yun, J., & Xia, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018219 · Cited by 146
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
Derks, S., Nason, K. S., Liao, X., Stachler, M. D., Liu, K. X., Liu, J. B., Sicińska, E., Goldberg, M. S., Freeman, G. J., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0046 · Cited by 140
Dolled-Filhart, M. P., Locke, D., Murphy, T., Lynch, F., Yearley, J. H., Frisman, D. M., Pierce, R., WEINER, R. S., Wu, D., & Emancipator, K. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0544-oa · Cited by 95
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Jin, Z., & Yoon, H. H. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.06 · Cited by 91
Lu, B., Chen, L., Liu, L., Zhu, Y., Wu, C., Jiang, J., & Zhang, X. (2011) · Immunologic Research · doi:10.1007/s12026-011-8227-9 · Cited by 67
Cited by
Kojima, T., Shah, M. A., Muro, K., Francois, E., Adenis, A., Hsu, C.-H., Doi, T., Moriwaki, T., Kim, S.-B., Lee, S.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01888 · Cited by 1,126
Self-citationAjani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0033 · Cited by 1,059
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Self-citationWang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Shah, M. A., Kojima, T., Hochhauser, D., Enzinger, P., Raimbourg, J., Hollebecque, A., Lordick, F., Kim, S.-B., Tajika, M., Kim, H. T., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5441 · Cited by 496
Self-citation
Metadata
- Authors
- Doi, T., Piha-Paul, S. A., Jalal, S. I., Saraf, S., Lunceford, J., Koshiji, M., & Bennouna, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-01-01
- Volume
- 36
- Issue
- 1
- Pages
- 61-67
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2767857925
- Cited by
- 318
- References
- 25
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.